On one hand, primary CRC tumors harbor MHC-low TAMs with impaired antigen presentation, liver metastases are enriched with THBS1+ MHC-low TAMs that express pro-angiogenic factors and genes like THBS1 and MARCO, supporting tumor progression (Che et al., 2021). The gene discussed is HLA-C; the disease is neoplasm.